Rahul Sahgal – CEO, Swiss-American Chamber of Commerce
Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to…
The Swiss-American Chamber of Commerce plays a vital and active role in assisting Swiss companies in the United States and U.S. companies in Switzerland to expand their business. The Swiss-American Chamber of Commerce is a not-for-profit organization.
Relations between Switzerland and the United States of America are extremely diverse and enjoy a rich tradition. The United States is the second largest export market for Switzerland and an important hub for education and research. Over the last 12 years, exports to America have doubled in volume, going from 10.6 to 14.5 percent of all Swiss exports between 2004 and today. Swiss pharmaceutical exports account for approximately 47 percent of trade with America.
Contact
Talacker 41, 8001 Zurich, Switzerland, Phone: +41 43 443 72 00
Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to…
In a wide-ranging conversation, Martin Naville of AmCham Switzerland looks at the evolution of the Switzerland-US trade relationship and the importance of pharma within it, the pressing need for a…
Martin Naville, CEO of the Swiss-American Chamber of Commerce, discusses Swiss exports to the US, global competitiveness and innovation rankings, and why the Swiss-US relationship will only continue to grow…
Europe and Canada (EUCAN) have an essential role in Takeda’s global mission to advance healthcare innovation. Ricardo Marek, President of Takeda’s EUCAN division, discusses the operational and regulatory challenges, the…
Fabrice Véricel and Geoffrey Folie explore UCB’s strategic growth, highlighting its European sites in Braine-l’Alleud, Belgium and Bulle, Switzerland and their roles in global pharmaceutical production. Key topics include the…
Jérôme Garcin, newly appointed General Manager of Bristol-Myers Squibb (BMS) Switzerland, shares his journey to the role and discusses the strategic importance of the Swiss affiliate within the global BMS…
Giuseppe Grossi, General Manager of Daiichi Sankyo Switzerland, delves into the company’s strategic growth in cardiovascular and oncology, its commitment to innovation, and its dedication to making a meaningful impact…
Anne Mette Wiis Vogelsang, CVP & General Manager of Novo Nordisk Switzerland, discusses Switzerland’s progressive healthcare landscape while addressing key issues like diabetes care, obesity, and systemic healthcare challenges. Vogelsang…
Bachem’s Thomas Meier highlights the company’s pivotal role as a CDMO in the rapidly evolving peptide and oligonucleotide markets, emphasizing strategic expansions, innovative manufacturing techniques, and a deep commitment to…
Hendrik von Waldburg, Country Manager of Angelini Pharma S.p.A., Rom, Zweigniederlassung Zug, shares insights into the company’s ambitious vision for brain health and its expanding presence in the Swiss market.…
In conversation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 in Madrid, Roche Diagnostics’ Margherita Carboni discusses the potential of blood-based biomarkers to transform Alzheimer’s diagnostics, offering a faster and…
Dennis Engelke, General Manager for Switzerland and Austria at Jazz Pharmaceuticals, discusses his career trajectory and the company’s growth in these markets. He highlights Jazz’s commitment to patient access and…
Michael Kubischik shares his career journey and Sanofi’s strategic focus in Switzerland. He highlights Sanofi’s dedication to become the world´s leading immunology company, supported by initiatives like AI integration and…
Georg Pirmin Meyer, SVP and Head of International at Blueprint Medicines, shares insights into the company’s journey from a promising startup to a fast-scaling biotech leader focused on allergy/inflammation and…
Patrick Leimgruber of UPSA discusses the company’s strategic growth roadmap and ambitions to expand its product portfolio and reach EUR 1 billion in net sales by 2027. He also outlines…
See our Cookie Privacy Policy Here
